BIOGEN INC. Treasury Stock, Shares, Acquired
Shares the company repurchased and the cash it paid, as filed in its 10-Q and 10-K XBRL (statement of shareholders' equity and cash flow statement).
- BIOGEN INC. treasury stock, shares, acquired for the quarter ending 2025-09-30 was 0.00 shares.
- BIOGEN INC. treasury stock, shares, acquired for the quarter ending 2025-06-30 was 0.00 shares.
- BIOGEN INC. treasury stock, shares, acquired for the quarter ending 2024-12-31 was 0.00 shares.
- BIOGEN INC. treasury stock, shares, acquired for the quarter ending 2024-09-30 was 0.00 shares.
- BIOGEN INC. treasury stock, shares, acquired for fiscal 2024 was 0.00 shares.
- BIOGEN INC. treasury stock, shares, acquired for fiscal 2023 was 0.00 shares.
- BIOGEN INC. treasury stock, shares, acquired for fiscal 2016 was 3.30M shares, a 80.36% decline from fiscal 2015.
- BIOGEN INC. treasury stock, shares, acquired for fiscal 2015 was 16.80M shares, a 479.31% increase from fiscal 2014.
| Period end | Treasury Stock, Shares, Acquired 3 month | Treasury Stock, Shares, Acquired 12 month |
|---|---|---|
| 2025-09-30 | 0.00 shares 10-Q · filed 2025-10-30 | |
| 2025-06-30 | 0.00 shares 10-Q · filed 2025-07-31 | |
| 2024-12-31 | 0.00 shares derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-12 | 0.00 shares 10-K · filed 2025-02-12 |
| 2024-09-30 | 0.00 shares 10-Q · filed 2025-10-30 | |
| 2024-06-30 | 0.00 shares 10-Q · filed 2025-07-31 | |
| 2023-12-31 | 0.00 shares 10-K · filed 2025-02-12 | |
| 2022-09-30 | 1.20M shares 10-Q · filed 2023-11-08 | |
| 2022-06-30 | 2.40M shares 10-Q · filed 2023-07-25 | |
| 2016-12-31 | 2.20M shares derived: 10-K 12 month − 10-Q 9 month · filed 2017-02-02 | 3.30M shares 10-K · filed 2017-02-02 |
| 2015-12-31 | 7.10M shares derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-01 | 16.80M shares 10-K · filed 2018-02-01 |
| 2015-09-30 | 9.60M shares derived: 10-Q 9 month − 10-Q 6 month · filed 2016-10-26 | |
| 2014-12-31 | 1.70M shares derived: 10-K 12 month − 10-Q 9 month · filed 2017-02-02 | 2.90M shares 10-K · filed 2017-02-02 |
| 2014-09-30 | 0.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2015-10-21 | |
| 2013-12-31 | 0.00 shares derived: 10-K 12 month − 10-Q 9 month · filed 2015-02-04 | 2.00M shares 10-K · filed 2015-02-04 |
| 2013-09-30 | 1.70M shares 10-Q · filed 2013-10-28 | 2.10M shares derived: sum of 4 quarters · filed 2014-07-23 |
| 2013-06-30 | 0.00 shares derived: 10-Q 6 month − 10-Q 3 month · filed 2014-07-23 | 800.00K shares derived: sum of 4 quarters · filed 2014-07-23 |
| 2013-03-31 | 300.00K shares 10-Q · filed 2014-04-23 | 4.10M shares derived: sum of 4 quarters · filed 2014-04-23 |
| 2012-12-31 | 100.00K shares derived: 10-K 12 month − 10-Q 9 month · filed 2014-02-06 | 7.80M shares 10-K · filed 2014-02-06 |
| 2012-09-30 | 400.00K shares 10-Q · filed 2012-10-25 | 8.70M shares derived: sum of 4 quarters · filed 2013-04-25 |
| 2012-06-30 | 3.30M shares 10-Q · filed 2012-07-24 | 8.30M shares derived: sum of 4 quarters · filed 2013-04-25 |
| 2012-03-31 | 4.00M shares 10-Q · filed 2013-04-25 | 7.20M shares derived: sum of 4 quarters · filed 2013-04-25 |
| 2011-12-31 | 1.00M shares derived: 10-K 12 month − 10-Q 9 month · filed 2013-02-05 | 6.00M shares 10-K · filed 2013-02-05 |
| 2011-09-30 | 0.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2012-10-25 | |
| 2011-06-30 | 2.20M shares derived: 10-Q 6 month − 10-Q 3 month · filed 2012-07-24 | |
| 2011-03-31 | 2.80M shares 10-Q · filed 2012-05-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Revolution Medicines, Inc. (RVMD) | United States | $42.805B | -22.69 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |